[
  {
    "ts": null,
    "headline": "Why Merck & Co., Inc. (MRK) is the Best Pharma Stock to Buy According to Hedge Funds",
    "summary": "We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other best pharma stocks to buy according to hedge funds. Why is China the Talk of the Town […]",
    "url": "https://finnhub.io/api/news?id=b6b2ddbb1e2313ce701b492bf311cbdcea8e4497d5785c734d6fc76fa71fbb46",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741804340,
      "headline": "Why Merck & Co., Inc. (MRK) is the Best Pharma Stock to Buy According to Hedge Funds",
      "id": 133184625,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other best pharma stocks to buy according to hedge funds. Why is China the Talk of the Town […]",
      "url": "https://finnhub.io/api/news?id=b6b2ddbb1e2313ce701b492bf311cbdcea8e4497d5785c734d6fc76fa71fbb46"
    }
  },
  {
    "ts": null,
    "headline": "Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025",
    "summary": "On Wednesday, Merck & Co Inc (NYSE:MRK) announced the presentation of results from two Phase 3 trials of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection that is virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamidei (BIC/FTC/TAF) in trial MK-8591A-052) or antiretroviral therapy (bART) in trial MK-8591A-051. In both trials, DOR/ISL met the primary efficacy success criterion for non-inferiority to comparator antiretroviral therapies and primary safety objective",
    "url": "https://finnhub.io/api/news?id=21c1db561809fbfcc9a74421499ef4eb3e85d1eba5fee492b4dbf34064a7e8a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741800637,
      "headline": "Merck Plans Regulatory Submission For Two-Drug Regime For HIV Infection By Mid-2025",
      "id": 133184626,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "On Wednesday, Merck & Co Inc (NYSE:MRK) announced the presentation of results from two Phase 3 trials of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection that is virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamidei (BIC/FTC/TAF) in trial MK-8591A-052) or antiretroviral therapy (bART) in trial MK-8591A-051. In both trials, DOR/ISL met the primary efficacy success criterion for non-inferiority to comparator antiretroviral therapies and primary safety objective",
      "url": "https://finnhub.io/api/news?id=21c1db561809fbfcc9a74421499ef4eb3e85d1eba5fee492b4dbf34064a7e8a5"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
    "summary": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=38b7c728fe2f896a6b0a044d7284b923bddd68b992cd7cef2c7d609d542dcaca",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741797120,
      "headline": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
      "id": 133171085,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=38b7c728fe2f896a6b0a044d7284b923bddd68b992cd7cef2c7d609d542dcaca"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48",
    "summary": "RAHWAY, N.J., March 12, 2025--Merck Announces Data from Phase 3 Trials that Show Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir Maintained HIV-1 Viral Suppression",
    "url": "https://finnhub.io/api/news?id=e773f045e3437294c862736ddf6e9eb902a7ea46a836783bb5b29497cef3eef9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741793160,
      "headline": "Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48",
      "id": 133184627,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., March 12, 2025--Merck Announces Data from Phase 3 Trials that Show Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir Maintained HIV-1 Viral Suppression",
      "url": "https://finnhub.io/api/news?id=e773f045e3437294c862736ddf6e9eb902a7ea46a836783bb5b29497cef3eef9"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK): Among Dobermans of the Dow to Buy",
    "summary": "We recently published a list of Dobermans of the Dow: 10 Stocks to Consider. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other Dobermans of the Dow to buy. The Dobermans of the Dow strategy serves as an alternative to the well-known Dogs of […]",
    "url": "https://finnhub.io/api/news?id=a2ec79984160c3695f68b173aad784d669078d30d7352a1e76c444187feb0d0e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741788675,
      "headline": "Merck & Co., Inc. (MRK): Among Dobermans of the Dow to Buy",
      "id": 133184628,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published a list of Dobermans of the Dow: 10 Stocks to Consider. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other Dobermans of the Dow to buy. The Dobermans of the Dow strategy serves as an alternative to the well-known Dogs of […]",
      "url": "https://finnhub.io/api/news?id=a2ec79984160c3695f68b173aad784d669078d30d7352a1e76c444187feb0d0e"
    }
  },
  {
    "ts": null,
    "headline": "Caterpillar: Diversification Without Diworsification; Home Depot Looks Healthy, So Do Others",
    "summary": "Diversify Caterpillar holdings with tax-efficient strategies. Explore HD, LOW, and SNA for income replacement potential and strong dividend growth.",
    "url": "https://finnhub.io/api/news?id=9cf9ca56103d930886a81f4fb47de06448e6f9ac30502d33ccf692493d220c13",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741786147,
      "headline": "Caterpillar: Diversification Without Diworsification; Home Depot Looks Healthy, So Do Others",
      "id": 133156626,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2033001899/image_2033001899.jpg?io=getty-c-w750",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Diversify Caterpillar holdings with tax-efficient strategies. Explore HD, LOW, and SNA for income replacement potential and strong dividend growth.",
      "url": "https://finnhub.io/api/news?id=9cf9ca56103d930886a81f4fb47de06448e6f9ac30502d33ccf692493d220c13"
    }
  },
  {
    "ts": null,
    "headline": "Merck Announces Positive Data From Phase 3 Trials Of Doravirine/Islatravir",
    "summary": "Merck & Co Inc: * MERCK ANNOUNCES POSITIVE DATA FROM PHASE 3 TRIALS THATSHOW THEINVESTIGATIONAL, ONCE-DAILY, ORAL, TWO-DRUG REGIMEN OFDORAVIRINE/ISLATRAVIR MAINTAINED HIV-1...",
    "url": "https://finnhub.io/api/news?id=b564f29842452ac0b294df624e11c8e5ad6333b5ef122b510d0b4868282caeaf",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741784946,
      "headline": "Merck Announces Positive Data From Phase 3 Trials Of Doravirine/Islatravir",
      "id": 133156157,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck & Co Inc: * MERCK ANNOUNCES POSITIVE DATA FROM PHASE 3 TRIALS THATSHOW THEINVESTIGATIONAL, ONCE-DAILY, ORAL, TWO-DRUG REGIMEN OFDORAVIRINE/ISLATRAVIR MAINTAINED HIV-1...",
      "url": "https://finnhub.io/api/news?id=b564f29842452ac0b294df624e11c8e5ad6333b5ef122b510d0b4868282caeaf"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Select Health Care Portfolio Q4 2024 Review",
    "summary": "Health care stocks returned -9.75% in the final quarter of 2024, according to the MSCI U.S. IMI Health Care 25/50 Index, widely lagging the 2.41% gain of the broad-based S&P 500Â® index.",
    "url": "https://finnhub.io/api/news?id=0d949fbfb9bc6d781dd942fc4d702b6a460558e2a5372e95abd05eb5e16657ae",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741773660,
      "headline": "Fidelity Select Health Care Portfolio Q4 2024 Review",
      "id": 133149109,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/183355336/image_183355336.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Health care stocks returned -9.75% in the final quarter of 2024, according to the MSCI U.S. IMI Health Care 25/50 Index, widely lagging the 2.41% gain of the broad-based S&P 500Â® index.",
      "url": "https://finnhub.io/api/news?id=0d949fbfb9bc6d781dd942fc4d702b6a460558e2a5372e95abd05eb5e16657ae"
    }
  },
  {
    "ts": null,
    "headline": "Class Action Filed Against Merck & Co., Inc. (MRK) - April 14, 2025 Deadline to Join - Contact Levi & Korsinsky",
    "summary": "NEW YORK, March 12, 2025 /PRNewswire/ --  Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. of a class action securities lawsuit. ...",
    "url": "https://finnhub.io/api/news?id=ce623f0a5d4a7d131064250729c3fa87e235483f3a1f5ede1a593bdf0e6da72f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741758384,
      "headline": "Class Action Filed Against Merck & Co., Inc. (MRK) - April 14, 2025 Deadline to Join - Contact Levi & Korsinsky",
      "id": 133147382,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "NEW YORK, March 12, 2025 /PRNewswire/ --  Levi & Korsinsky, LLP notifies investors in Merck & Co., Inc. of a class action securities lawsuit. ...",
      "url": "https://finnhub.io/api/news?id=ce623f0a5d4a7d131064250729c3fa87e235483f3a1f5ede1a593bdf0e6da72f"
    }
  }
]